-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Evaluation of the anti-tumor efficacy of IHMT-EZH2-115 in a xenograft mouse model
Recently, researchers led by Professor Liu Qingsong, Hefei Institute of Material Science, Chinese Academy of Sciences, discovered an effective selective zeste homolog 2 (EZH2) enhancer inhibitor ihht-EZH2-115 for the treatment of b-cell lymphoma
.
EZH2 is the enzyme subunit of polycomb inhibition complex 2
.
As a therapeutic target for the treatment of cancer, it has been extensively studied
In this study, the researchers started with EPZ6438, which showed anti-b-cell lymphoma effects in preclinical models.
Under the guidance of computer-aided drug design, the researchers used focused medicinal chemistry methods to obtain IHMT-EZH2-115
.
Biochemical analysis showed that IHMT-EZH2-115 had a strong inhibitory effect on EZH2 wild type and mutant type
.
At the same time, it shows high selectivity for a wide range of histone methyltransferases
In vivo, IHMT-EZH2-115 showed good oral pharmacokinetic characteristics in two mouse models of diffuse large b-cell lymphoma with EZH2 mutations, Pfeiffer (EZH2 A677G) and karpas422 (EZH2 Y641N), and showed Dose-dependent anti-tumor effect
These results indicate that IHMT-EZH2-115 may be a potential candidate gene for clinical development of EZH2 mutation-driven tumors
